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SLEDAIAbstract Aim of the work: To assess the carotid intima-media thickness (IMT) and plaque forma-
tion in systemic lupus erythematosus (SLE) patients with and without antiphospholipid syndrome
(APS) by doppler ultrasonography and to correlate it with the clinical features, disease activity and
damage.
Patients and methods: Thirty-six female SLE patients with secondary APS and another 36
without were included. Thirty-six matching healthy volunteers were included as control. In patients,
the disease activity and damage were assessed using the SLE Disease Activity Index (SLEDAI) and
Systemic Lupus International Collaborating Clinics (SLICC) index, respectively. Doppler ultra-
sound was carried out for patients and control and the IMT was measured.
Results: The demographic and clinical characteristics of patients are presented. The disease
activity was signiﬁcantly higher in SLE patients with APS (19.7 ± 7.9) compared to SLE only
patients (15.1 ± 9.2) (p= 0.03). The low density lipoprotein (LDL) was signiﬁcantly increased in
APS patients (p= 0.04). The IMT was comparable between both groups (0.83 ± 0.15 mm) vs
(0.86 ± 0.2 mm) (p= 0.55) and both were signiﬁcantly increased compared to the control
(0.61 ± 0.11 mm) (p< 0.0001). The dyslipidemia present in the patients showed a signiﬁcant
difference in the measured lipid proﬁle parameters (p< 0.0001). The IMT signiﬁcantly correlated
with the SLEDAI in both groups (p< 0.002 and <0.001 respectively).
Conclusion: The increased IMT as a marker of atherosclerosis is conﬁrmed in SLE patients with
no obvious difference in those with secondary APS. The link between the increased IMT and disease
activity favors the role of disease-speciﬁc potential risk factors, in addition to the traditional con-
ventional ones, in the development of atherosclerosis.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
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Systemic lupus erythematosus (SLE) is a chronic and multisys-
temic autoimmune disorder [1,2]. It may result from disturbed
tolerance to self antigens and development of auto-antibodies
leading to the formation of immune complexes. These immune
deposits in the tissues initiate an inﬂammatory response by
activating the complement cascade and recruiting inﬂammatory
cells [3,4]. The defective clearance of apoptotic cells [5];
increased oxidative stress [6] and gene polymorphism [7] are
believed to be among the multiple causes of SLE. Despite
improved prognosis, SLE patients remain at increased risk for
early death as vascular events occurwith increased frequency [8].
The most common cause of death in SLE patients affected
by disease for more than 5 years is cardiovascular disease
(CVD) [2,9]. The IMT has been found to be increased in many
rheumatic diseases such as rheumatoid arthritis [10], SLE
[11,12], Behcets disease [13] and osteoarthritis [14]. Together
with classical conventional risk factors, other mechanisms (dis-
ease-speciﬁc factors) promote accelerated atherosclerosis in
SLE. Traditional CVD risk factors include age, hypertension,
diabetes mellitus, dyslipidemia, previous vascular event, meno-
pause and smoking. The nontraditional factors include lupus
nephritis (LN), presence of pro-inﬂammatory cytokines,
inﬂammatory mediators, antiphospholipid (APL) antibodies
and corticosteroid use [2]. Recent evidence strongly suggests
that atherosclerotic plaque is largely driven by inﬂammation
and an active immunological response, in contrast to the
long-held belief that plaque is a passive accumulation of lipids
in the arterial wall [9].
The antiphospholipid syndrome (APS) was ﬁrst described
in the early 1980s. The term was coined to describe patients
presenting with recurrent arterial and venous thrombosis or
pregnancy complications. It was ﬁrst reported in SLE patients,
but later on it became obvious that SLE is not a necessary con-
dition for its occurrence. Antibodies to phospholipids were
found to play a central role in the disease, hence its name.
The main hindrance to an accurate diagnosis was the lack of
standardized antiphospholipid (APL) antibody testing and
lately a combination of tests has been acknowledged [15].
The role of APL antibodies in atherosclerosis development in
SLE remains unclear [16].
The aim of the present study was to assess the carotid
intima-media thickness (IMT) and plaque formation in SLE
patients with and without APS by Doppler ultrasonography
(US) and to correlate it with the clinical features, disease activ-
ity and damage.
2. Patients and methods
Thirty-six female SLE patients with deﬁnite secondary APS
diagnosed according to the International consensus statement
on classiﬁcation criteria [17] were recruited. Another 36 female
SLE patients without APS were also included. All patients ful-
ﬁlled the Systemic Lupus International Collaborating Clinics
(SLICC) classiﬁcation criteria for SLE [18] and were recruited
from the Rheumatology and Internal medicine out-patient
Clinics of Cairo University Hospitals. Thirty-six age and sex
matched healthy volunteers were included as a control group.
Full history taking, thorough clinical examination and
relevant laboratory investigations were performed for all thepatients. Disease activity was assessed using the Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI) [19]
while assessment of organ damage was made using the
Systemic Lupus International Collaborating Clinics/ACR
(SLICC/ACR) index [20].
Doppler ultrasound scan was carried out for patients and
control. The intima-media thickness (IMT) measurements on
each side were taken at the common carotid artery (CCA)
(10 mm before and 5–10 mm cranially to the start of the
bulb) and the internal carotid artery 10 mm after the ﬂow
divider. For each patient the highest IMT among the mea-
sured segments studied on each side was recorded and the
mean value calculated. According to current sonographic
criteria the IMT was considered ‘‘normal’’ when less than
0.9 mm, ‘‘thickened’’ when the IMT was equal to or more
than 0.9 mm and when the thickness was more than
1.3 mm was indicative of atherosclerotic plaque [21].
The study was in accordance to the ethical standards of the
Helsinki declaration. Informed consent was obtained from all
participants prior to the study.
Statistical analysis: Statistical Package for Social Science
(SPSS) program version 15 was used for analysis of data.
Data were presented as mean ± SD. Mann–Whitney test
was used for the comparison analysis of two non-parametric
quantitative and Chi square test for qualitative variables.
The one way ANOVA was used to compare more than 2
groups. Spearman0s correlation was used for the detection of
the relation between two non-parametric variables. p-Value
was considered signiﬁcant if <0.05.
3. Results
The study included 72 SLE female patients divided into 2
groups according to the presence of secondary APS. The
demographic and clinical characteristics of patients are pre-
sented in Table 1. None of the patients was menopausal or
smoking. None of the patients was diabetic. All patients were
receiving oral corticosteroids and cyclophosphamide was
received in 18 SLE patients and in 15 with APS. The study
included 36 age and sex matched healthy controls with a mean
age of 28.1 ± 5.7 years. The body mass index (26.2 ± 3.02)
was also comparable to patients.
The risk factors for atherosclerosis and IMT are presented
in Table 2. The lipid proﬁle of the control showed; choles-
terol (124.2 ± 40.6 mg/dl), triglycerides (92.5 ± 30.8 mg/dl),
high density lipoprotein (HDL) (67.4 ± 14.4 mg/dl) and low
density lipoprotein (LDL) (53.6 ± 7.4 mg/dl). The dyslipi-
demia present in the patients showed a signiﬁcant difference
in the values of the measured lipid proﬁle parameters
(p< 0.0001).
The IMT in the control was 0.61 ± 0.11 mm and the thick-
ness was signiﬁcantly increased in patients (<0.0001) (Fig. 1).
In SLE patients with APS there was an increased IMT found
in 18 (50%) and none had plaques while in the SLE only
patients, 14 (38.9%) had an increased IMT of which 3 had pla-
ques. The medications received had no effect on the IMT.
Correlations of the IMT in SLE patients with and without
APS are presented in Table 3. On regression analysis , in SLE
patients with secondary APS, all the variables including the
age, disease duration, lipid proﬁle, urinary protein, SLEDAI
and SLICC were predictors of the IMT (p< 0.0001); while
Table 1 Demographic and clinical characteristics of systemic
lupus erythematosus patients.
Characteristic SLE + APS (36) SLE (36) p
Age (years) 29.0 ± 6.8 27.9 ± 6.9 0.5
Disease duration (years) 7.1 ± 6.3 4.1 ± 2.6 0.01
ESR (mm/1st h) 60.7 ± 36.8 59.3 ± 23.7 0.86
Serum creatinine (mg/dl) 0.73 ± 0.25 0.85 ± 0.3 0.51
24 h urine protein 0.88 ± 0.81 1.1 ± 1.5 0.44
Anti-DNA positivity 21 (58.3) 27 (75) 0.14
Anti-Ro positivity 12 (33.3) 14 (38.9) 0.39
Steroid dose (mg/day) 21.9 ± 6.5 24.5 ± 12.2 0.26
Manifestations
Pulmonary 12 (33.3) 21 (58.3) 0.03
Cardiac 6 (16.7) 4 (11.1) 0.5
Renal 18 (50) 25 (69.4) 0.1
Neuropsychiatric 18 (50) 15 (41.7) 0.49
Arthritis 12 (33.3) 13 (36.1) 0.81
Indices
SLEDAI 19.7 ± 7.9 15.1 ± 9.2 0.03
SLICC 2.5 ± 1.8 1.9 ± 2.2 0.18
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index,
SLICC: Systemic Lupus International Collaborating Clinics.
Results are presented as mean ± SD or N (%). Bold values indicate
a signﬁcant difference.
Table 2 Risk factors for atherosclerosis and IMT of the
systemic lupus erythematosus patients.
Factor SLE+ APS (36) SLE (36) p
Body mass index (BMI) 27.7 ± 3.8 25.7 ± 2.4 0.5
Hypertension N (%) 12 (33.3) 15 (41.7) 0.47
Cholesterol (mg/dl) 222.7 ± 49.9 224.8 ± 53.7 0.86
Triglycerides (mg/dl) 207.7 ± 74.4 184.7 ± 76.6 0.2
HDL (mg/dl) 42.6 ± 10.7 43.4 ± 12.6 0.76
LDL (mg/dl) 161.3 ± 36.4 141.8 ± 42.6 0.04
IMT (mm) 0.83 ± 0.15 0.86 ± 0.2 0.55
HDL: high density lipoprotein, LDL: low density lipoprotein,
IMT: intima-media thickness. Results are presented as mean ± SD
or N (%). Bold values indicate a signﬁcant difference.
Fig. 1 The intima-media thickness in systemic lupus erythema-
tosus patients with and without antiphospholipid syndrome and
the control.
Table 3 Correlation of the intima-media thickness in SLE
patients with and without antiphospholipid syndrome with
different parameters.
Parameter Intima-media thickness (mm)
SLE + APS SLE
Age (years) 0.64 (<0.001) 0.22 (0.20)
Disease duration (years) 0.11 (0.54) 0.08 (0.67)
Body mass index 0.16 (0.36) 0.40 (0.60)
Cholesterol (mg/dl) 0.24 (0.17) 0.25 (0.14)
Triglycerides (mg/dl) 0.14 (0.4) 0.43 (0.009)
HDL (mg/dl) 0.34 (0.046) 0.27 (0.11)
LDL (mg/dl) 0.02 (0.9) 0.22 (0.19)
Urinary protein (g/24 h) 0.27 (0.12) 0.33 (0.053)
Creatinine (mg/dl) 0.50 (0.10) 0.78 (0.23)
Anti-dsDNA 0.40 (0.02) 0.17 (0.32)
Steroid dose (mg/day) 0.14 (0.43) 0.15 (0.38)
SLEDAI 0.49 (0.002) 0.59 (<0.001)
SLICC 0.13 (0.46) 0.30 (0.08)
HDL: high density lipoprotein, LDL: low density lipoprotein,
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index,
SLICC: Systemic Lupus International Collaborating Clinics. Bold
values indicate a signﬁcant difference.
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signiﬁcant risk factors (p0.012 and p0.047 respectively).
4. Discussion
Systemic lupus erythematosus is known to be one of the stron-
gest risk factors for atherosclerosis. Patients with SLE have an
excess cardiovascular risk compared with general population,
leading to increased cardiovascular morbidity and mortality.
Although the precise explanation for this is yet to be estab-
lished, it seems to be associated with the presence of an accel-
erated atherosclerotic process, arising from the combination of
traditional and lupus-speciﬁc risk factors [1]. The CVD risk
among SLE patients compared with the general population
is at least doubled. While older SLE patients appear to have
the highest absolute risks of CVD, young women have alarm-
ingly high relative risks. Both traditional and SLE-speciﬁc risk
factors are important, although there are discrepancies withinthe literature [22,23]. Traditional risk factors do not fully
explain this increased risk of CVD thus strongly suggesting
that autoimmunity contributes to accelerated atherosclerosis.
Altered immune system function is recognized as the primary
contributor to both the initiation and progression of athero-
sclerosis. Multiple manifestations of autoimmunity, including
changes in cytokine levels and innate immune responses,
autoantibodies, adipokines, dysfunctional lipids and oxidative
stress, could heighten the atherosclerotic risk. SLE-speciﬁc
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development of a comprehensive, clinically feasible biomarker
panel could be invaluable for the identiﬁcation and treatment
of patients at risk of developing accelerated atherosclerosis
[23].
The increased IMT in SLE in the present study has been
conﬁrmed in several studies [24–26]. Furthermore, in other
studies on Egyptian SLE patients, the IMT was found to be
signiﬁcantly increased [11,12,27].
In the present study, the signiﬁcant correlation of the IMT
with the disease activity in all SLE may throw light on the pos-
sible role of inﬂammation in determining the thickness of the
intima-media in SLE patients with or without APS and should
be considered among the risk factors and not just the tradi-
tional atherosclerotic factors. In those patients with APS, there
was a signiﬁcant correlation of the IMT with the anti-DNA
positivity. In other recent studies, the SLEDAI was
signiﬁcantly associated with carotid IMT [11,28]. In the study
of Shang et al. [30] the patients with active disease
(SLEDAIP 3) had signiﬁcantly higher carotid augmentation
index (CAI) than inactive ones. After making adjustments
for age, body mass index (BMI) and blood pressure, carotid
AI rather than the IMT was found to signiﬁcantly correlate
with the SLEDAI. They concluded that SLE was an indepen-
dent risk factor of sub-clinical atherosclerosis and arterial stiff-
ness may identify the presence of active disease. Furthermore,
in a follow-up study, there was no signiﬁcant association
between SLEDAI, anti-dsDNA and anti-phospholipid with
the progression of subclinical atherosclerosis [31].
In the present study, there was no signiﬁcant difference in
the frequency of increased IMT in SLE patients with or with-
out APS. It has been reported that the role of antiphospholipid
(APL) antibodies in premature CVD remains a matter of
debate. b2-Glycoprotein I, abundantly found in vascular pla-
ques, has been hypothesized to be protective against athero-
sclerosis development. Antibodies against this molecule
could, in theory, be detrimental to the vessel wall and promote
the activation of inﬂammatory cascades by immune-complex
formation. However, it has been found that early markers of
CVD risk were not different compared with age and gender
matched healthy controls [16]. Previous studies showed that
the presence of APL antibodies did not correlate with endothe-
lial dysfunction or carotid IMT in SLE [16,32,33].
In the present study, LDL was signiﬁcantly higher in SLE
patients with APS compared to those without. Furthermore,
there was a signiﬁcant correlation of the IMT with the
triglycerides in SLE only patients and negatively with HDL
in those patients with APS. Even though APS and athero-
sclerosis share several similar features as increased levels of
antibodies to oxidized low density lipoprotein (oxLDL) and
phospholipids, endothelial dysfunction, platelet activation
and thrombus formation, increased oxidative stress and
immune cell activation, the epidemiologic evidence that the
presence of APL Abs may be a serologic marker or an
independent risk factor for atherosclerosis is inconclusive
[34–36]. Accelerated atherosclerosis is considered a leading
cause of morbidity and mortality in SLE which conﬁrms the
importance of recognizing and controlling modiﬁable risk fac-
tors, even in asymptomatic patients [37]. Hypercholesterolemia
increases the risk of clinical or subclinical atherosclerosis in
SLE. Established risk factors are important, but do not fully
explain the increased frequency of atherosclerosis in SLEand its cause is likely to be multifactorial [38,39].
Furthermore, it has been suggested that SLE is independently
associated with accelerated atherosclerosis [40]. Current
approaches to the prevention of atherosclerosis in SLE involve
targeting modiﬁable cardiac risk factors. Future preventive
strategies may include therapies that counteract the immuno-
logic responses that lead to plaque formation [9].
Antiphospholipid syndrome (APS) is the most frequent
cause of venous and arterial thrombotic events in
young patients. The accelerated atherosclerosis in APS is
linked-to the underlying associated systemic autoimmune
diseases, in particular, SLE. However, as arterial ischemic
events can occur in primary APS – with no other systemic
disorders – even in the absence of traditional cardiovascular
risk factors and overt atherosclerosis, this ﬁnding speaks in
favor of pro-coagulant activity of APL antibodies rather than
for their role in atherosclerotic plaque formation [41]. The link
between immune and inﬂammatory responses in the patho-
genesis of CVD has been ﬁrmly established; yet, despite our
increasing knowledge, accelerated atherosclerosis continues
to be a signiﬁcant co-morbidity and cause of mortality in
SLE [42].
In the present study, plaques were not found in those
patients with APS but were found in 3 (8.3%) of SLE only
cases. Patients in this study were of relatively young age. It
has been reported that carotid plaque can be detected in
21% of SLE patients under the age of 35 years and in up to
100% of those over the age of 65 years [16]. In another study
on Egyptian SLE patients, subclinical carotid plaque was
found in only 5% of the patients [12]. In another study on
SLE and the risk of carotid atherosclerosis, 50% of the
patients had carotid plaque [43].
Cardiovascular disease is a major complication of lupus
and a leading cause of death. Additional studies are needed
in order to identify the most effective preventive strategies
and most predictive vascular risk biomarkers [44]. No obvious
effect was detected of the medications received in the
present study on the IMT. It has been reported that multiple
SLE therapeutics seem to affect the development and
progression of atherosclerosis both positively and negatively
[23]. Development and establishment of new stratiﬁcation
tools to efﬁciently identify patients at increased cardiovascular
risk are essential. With advances in imaging techniques, the
ultimate goal of cardiovascular assessment will shift from
assessing symptomatic patients to diagnosing asymptomatic
early CVD which will hopefully help prevent its progression
[1].
Details of autoantibodies involved in APS should be con-
sidered in further studies in order to assess their role in the risk
of atherosclerosis in this subset of SLE patients. A study on a
larger number of patients and preferentially a longitudinally
designed one is recommended in future work. Extending the
study to include patients with primary APS may help to eluci-
date the role of the disease or its autoantibodies in the predic-
tion of atherosclerosis.
In conclusion, the increased IMT as a marker of
atherosclerosis is conﬁrmed in SLE patients with no obvious
difference in those with secondary APS. The link between
the increased IMT and the disease activity suggests the role
of disease-speciﬁc potential risk factors, in addition to the
traditional conventional ones, in the development of
atherosclerosis.
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